Patient: A 62-year-old former miner with silicosis of the lungs but otherwise in good general condition presented with a solid nodule in the nasal left lid area for a duration of three months. Because of a central ulceration the reference diagnosis was basalioma. The tumour infiltrated the nasal part of the upper and lower eyelid and the tear ducts so that these were unrinseable. Similar lesions have been present since two years in other skin regions.
Methods: Two cutaneous biopsies confirmed the diagnosis of a Mycosis fungoides without detectable expression of the CD30-antigen. Medical investigation finally revealed hepatosplenomegaly and cervical, inguinal and abdominal lymph node involvement. A lymph node biopsy three months after presentation again showed a T-cell-lymphoma which was CD30-positive now.
Therapy: Systemic polychemotherapy was started. The lid lesions completely resolved, and the tear ducts were rinseable again.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1055/s-2008-1035016 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Comparison of the efficacy of treatment with clobetasol propionate or bexarotene in early-stage mycosis fungoides.
An Bras Dermatol
December 2024
Dermatology Department, Şişli Hamidiye Etfal Training and Research Hospital, University of Health Sciences, Seyrantepe, İstanbul, Turkey.
Background: There are few studies in the literature comparing the effectiveness of topical treatments in early-stage mycosis fungoides (MF).
Objectives: It was aimed to evaluate the clinical efficacy, side effects and topical treatment compliance with bexarotene or clobetasol propionate in early-stage MF.
Methods: A total of 40 patients with stage IA-IB MF were enrolled in the study.
Case report: Canadian consensus on chlormethine gel use in mycosis fungoides-CTCL: literature review and real-world experience.
Front Med (Lausanne)
December 2024
Division of Radiation Oncology, University of Montreal, Montreal, QC, Canada.
Mycosis fungoides (MF) is the most common type of cutaneous T-cell lymphoma (CTCL), representing the majority of all lymphomas arising in the skin. The disease treatment focuses on managing symptoms and preventing disease evolution. To date, there is no gold standard for MF-CTCL treatment.
View Article and Find Full Text PDFPractical recommendations for therapy and monitoring of mogamulizumab patients in Germany.
J Dtsch Dermatol Ges
December 2024
Department of Dermatology, Venereology, Allergology and Phlebology, Johannes Wesling Clinic, University Hospital of the Ruhr University Bochum, Bochum, Germany.
Mycosis fungoides (MF) and Sézary syndrome (SS) are the most common subtypes of the heterogeneous group of cutaneous T-cell lymphomas (CTCL). With the expansion of the biologic treatment landscape, new treatment options have become available in recent years, most notably the C-C chemokine receptor 4 (CCR4)-directed monoclonal antibody mogamulizumab. Based on the phase III pivotal trial, mogamulizumab is recommended by the German S2k guidelines for the second-line treatment of stage IB and above SS and MF, after at least one prior systemic therapy.
View Article and Find Full Text PDFCorrigendum: Exploring the educational needs of patients with cutaneous lymphoma using an educational needs assessment tool.
Front Oncol
December 2024
Dermatology and Venereology Unit, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden.
[This corrects the article DOI: 10.3389/fonc.2024.
View Article and Find Full Text PDFSkin lymphomas in childhood: We only see what we know, we only know what we see.
J Eur Acad Dermatol Venereol
January 2025
Department of Dermatology and Allergology, Paracelsus Medical University Salzburg, Salzburg, Austria.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!